Abstract Background Select patients with locally advanced or metastatic renal cell carcinoma (RCC) are candidates for consolidative nephrectomy (CN) following immune checkpoint blockade (ICB). Existing cohorts have been limited by heterogeneous pathological assessment and small sample sizes, limiting validation of path...
Paulo Siqueira Do Amaral, R. Mehra, J. Gordetsky et al.· The Oncologist· 0 citations
Abstract Background Circulating tumor DNA (ctDNA) is an emerging tool for non-invasive disease monitoring in solid tumor oncology, yet its clinical utility in renal cell carcinoma (RCC) remains poorly defined. RCC exhibits variable ctDNA shedding rates, which may limit assay sensitivity particularly in low-burden disea...
Ezra Blumenthal, Paulo Siqueira Do Amaral, Yi Chen et al.· The Oncologist· 0 citations
Abstract Background Papillary renal cell carcinoma (pRCC) is the second most common histology of kidney cancer diagnosed in adults. However, the biologic drivers of recurrence after nephrectomy remain poorly defined, and no molecular biomarkers are routinely used in clinical practice to estimate prognosis. The primary...
W. J. Brewer, Joseph A. Vento, Ezra Blumenthal et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.